Investigating Psychopharmaceutical Effects on Early Vertebrate Development Using a Zebrafish Model System

Area of Science:

• Developmental Biology
• Neuroscience
• Pharmacology

Background:

• Cholesterol homeostasis is crucial for vertebrate development and nervous system function.
• Disrupted cholesterol can lead to developmental abnormalities, behavioral dysfunction, and increased mortality.
• Commonly prescribed psychopharmaceuticals may interfere with cholesterol synthesis, potentially affecting early development.

Purpose of the Study:

• To investigate the hypothesis that psychopharmaceutical exposure alters cholesterol biosynthesis, gene transcription, and early vertebrate development.
• To assess the impact of specific psychopharmaceuticals on whole-body and brain development, and nervous system function in a zebrafish model.
• To evaluate behavioral outcomes in zebrafish exposed to psychopharmaceuticals.

Main Methods:

• Utilized a high-throughput zebrafish model system to test psychopharmaceutical effects.
• Measured 7-dehydrocholesterol levels in zebrafish exposed to cariprazine, aripiprazole, trazodone, and AY9944.
• Analyzed gene expression, brain structure, and functional behaviors in treated zebrafish compared to controls.

Main Results:

• Exposure to cariprazine, aripiprazole, trazodone, and AY9944 increased 7-dehydrocholesterol levels.
• Significant alterations in disease-associated gene expression were observed in treated zebrafish.
• Psychopharmaceutical exposure led to observable differences in brain structure and functional behaviors.

Conclusions:

• Psychopharmaceuticals can disrupt cholesterol synthesis and impact early vertebrate development.
• The zebrafish model effectively identifies psychopharmaceutical effects on cholesterol metabolism, gene expression, and behavior.
• These findings highlight potential risks of psychopharmaceuticals to developmental processes and nervous system function.